Skip to main content
. 2018 Apr 25;24(8):1301–1307. doi: 10.1177/1076029618771750

Figure 1.

Figure 1.

Plasma sC5b-9 levels in patients with various thrombotic microangiopathy (TMA) conditions. Plasma samples obtained from patients with acute atypical hemolytic uremic syndrome (aHUS, n = 10), patients with chronic aHUS (n = 6), patients with thrombotic thrombocytopenic purpura (TTP, n = 11), patients with Shiga toxin-producing Escherichia coli–induced hemolytic uremic syndrome (STEC-HUS, n = 3), other TMA patients (n = 20), patients with systemic lupus erythematosus (SLE, n = 6), and healthy volunteers (HV, n = 96) were measured. *P < .05; **P < .01; ***P < .001.